Identification of canine parvovirus with the Q370R point mutation in the VP2 gene from a giant panda (Ailuropoda melanoleuca)

Ling Guo1, Shao-lin Yang1, Shi-jie Chen2, Zhihe Zhang3, Chengdong Wang3, Rong Hou3, Yupeng Ren4, Xintian wen1, Sanjie Cao1, Wanzhu Guo1, Zhongxiang Hao1, Zifang Quan1, Manli Zhang1 and Qi-gui Yan1,5*

Abstract

Background: In this study, we sequenced and phylogenetic analyses of the VP2 genes from twelve canine parvovirus (CPV) strains obtained from eleven domestic dogs and a giant panda (Ailuropoda melanoleuca) in China. A novel canine parvovirus (CPV) was detected from the giant panda in China.

Results: Nucleotide and phylogenetic analysis of the capsid protein VP2 gene classified the CPV as a new CPV-2a type. Substitution of Gln for Arg at the conserved 370 residue in CPV presents an unusual variation in the new CPV-2a amino acid sequence of the giant panda and is further evidence for the continuing evolution of the virus.

Conclusions: These findings extend the knowledge on CPV molecular epidemiology of particular relevance to wild carnivores.

Keywords: Canine parvovirus, VP2 gene, Point mutation, Phylogenetic analysis, Giant panda

Background

Canine parvovirus type 2 (CPV-2) is an important pathogen in domestic dogs and several wild carnivore species. It was first identified in USA in 1978 and was found later to have spread worldwide in domestic and wild canine populations. CPV-2 is a small non-enveloped, singe-stranded DNA virus (5.2 Kb) which is a member of the genus Parvovirus of the family Parvoviridae. The CPV genome is composed of two major ORFs, one encoding the two non-structural proteins [NS1 and NS2] and the other encoding the two capsid proteins [VP1 and VP2] [1]. There is also a third protein, VP3 which is produced by proteolytic processing of VP2.

CPV-2 is antigenically and genetically related to feline panleukopenia virus (FPLV). However, FPV infects cats, mink and raccoons, but not dogs, whereas CPV-2 infects dogs and other Canidae, but not cats. A few amino acid differences between CPV and FPV determine the specificity of these viruses [2]. After the CPV-2 initial appearance (during 1978–1981), two new antigenic variants, named CPV-2a and CPV-2b, were characterized [3-5]. The antigenic types CPV-2a and CPV-2b differ from the original CPV-2 in at least five or six amino acids/residues of the VP2 capsid protein (genomic positions 3045, 3685, 3699, 4062 and 4449) [6,7]. Canine parvovirus type 2a/2b having mutation at 297 residue (Ser→Ala) is designated as new CPV-2a/2b [8,9], residue 297 is located in a minor antigenic site close to epitope B and substitutions at this position may be responsible for changes in antigenicity of CPV variants [10]. Another antigenic variant having an amino acid substitution 426-Asp→Glu was reported for the first time in Italy [11] and had been reported from other countries [1,12-17], and this variant is currently named as CPV-2c.

It has been reported that canine parvovirus (CPV) have been implicated in disease and mortality in giant pandas [18-21], which is an endangered species native to the China. The giant pandas with CPV infection showed diarrhea, vomiting and water-like feces [18]. Giant panda parvovirus VP2 gene described here identifies yet another variant of the virus. It demonstrates the continued adaptation of the virus to an everexpanding host range...
that includes endangered species of wildlife. Understanding emergent disease threats is important in enabling effective conservation measures for endangered species.

**Results**

Out of 36 faecal samples of giant pandas and 97 canine rectal swabs screened by PCR assay using Hfor/Hrev primers, 1 giant panda and 62 dog samples yielded a specific amplicon of 611 bp, respectively.

The amplified PCR products of 11 randomly selected canine samples and one giant panda sample were subjected for sequencing using primer pair Hfor/Hrev. Primer pair Hfor/Hrev [11] encompasses informative amino acid residues which are of significance in characterizing the CPV types. All the CPV samples under study were found to be new CPV-2a (CPV-2a with nucleotide variation T→G at position 3675 or CPV-2a with amino acid variation 297-Ser→Ala). In comparison to prototype new-CPV-2a (AY742953), the samples under this study had amino acid residue variations at Tyr324Ile caused by mutation TAT→ATT at nt 3756–3758 of the VP2 gene. It was a unique mutation within the VP2 of Chinese and Korean strains of “new CPV-2a”. Critical positions of the CPV VP2 gene products of samples sequenced in this study are summarized in Table 1.

In addition to the nucleotide variations at positions 3675 and 3756, three additional mutations were observed in the canine parvovirus sequences under study. One was at nucleotide position 3584 where a mutation (U→A) resulting in the codon change from UUC→UAC, with amino acid variation 267-Phe→Tyr. All the sequences under this study except B03, B06 and B11 showed this variation. The second one was at nucleotide position 4110, where variation A→G was observed and which changed the codon from CAA→CGA, with amino acid variation 442-Thr→Ala. This variation (A→G) at nucleotide position 4110 was observed in strains A10, A11, A12, B01, B02, B05, B07 and B12 in this study (the dog samples). The last mutation was at nucleotide position 3894 where a mutation (A→G) resulting in the codon change from CAA→CGA, with amino acid variation 370-Gln→Arg. This variation only was revealed in strain B11 (the giant panda sample).

To analyse the phylogenetic relationships of the China isolates with other CPV strains isolated in various parts of the world, we constructed a maximum likelihood phylogenetic tree. The panda field isolate B11 was found to be phylogenetically closely related to new CPV-2a strains of Jilin strain CNJL0804. B06 and B03 are the closest of Chinese dog sequences examined in this study. Rest of the other sequences had distinct lineage but shared molecular relationship with new CPV-2a reference strains (Figure 1).

**Discussion**

New CPV-2a/2b appear to have replaced the prototype CPV-2a/2b strains and become the predominant types in many countries [22-26]. In China, the prevalent antigenic type in canine populations is type 2a, our results seem to confirm these data [27]. The dog and giant panda samples were all new CPV-2a, but it is impossible to conclude that new CPV-2a is predominant strain in the China dog or giant panda population because our data are limited to an exiguous number of samples and we do not have data regarding CPV-2 dog strains from the area where the giant panda samples were collected.

All the CPV clinical samples under study were found to be new CPV-2a (Figure 1). Similar substitution 297-Ser→Ala in CPV-2a/2b strains were reported in VP2 gene of CPV from worldwide [2,22,28-30]. This study detected one site mutation among the CPV-2a isolates in China: Tyr→Ile at position 324. This mutation was also

**Table 1 CPV strains from China, origin from which they were isolated and their GenBank accession numbers**

| Serial no | Strain | Host     | Foster mode | Vaccinated | Origins     | GenBank no. |
|-----------|--------|----------|-------------|------------|-------------|-------------|
| 1         | A10    | Dog      | Captive     | Yes        | Rectal swabs| JX624761    |
| 2         | A11    | Dog      | Captive     | Yes        | Rectal swabs| JX624762    |
| 3         | A12    | Dog      | Captive     | Yes        | Rectal swabs| JX624763    |
| 4         | B01    | Dog      | Captive     | Yes        | Rectal swabs| JX624764    |
| 5         | B02    | Dog      | Captive     | Yes        | Rectal swabs| JX624765    |
| 6         | B03    | Dog      | Captive     | Yes        | Rectal swabs| JX624766    |
| 7         | B04    | Dog      | Captive     | Yes        | Rectal swabs| JX624767    |
| 8         | B05    | Dog      | Captive     | Yes        | Rectal swabs| JX624768    |
| 9         | B06    | Dog      | Captive     | Yes        | Rectal swabs| JX624769    |
| 10        | B07    | Dog      | Captive     | Yes        | Rectal swabs| JX624770    |
| 11        | B11    | Giant panda | Captive     | Yes        | Faecal      | JX624771    |
| 12        | B12    | Dog      | Captive     | Yes        | Rectal swabs| JX624772    |
Figure 1 (See legend on next page.)
reported in 2009 [31]. Previous studies have shown that residue 324 is subject to strong positive selection in all parvoviruses of carnivores [32].

The natural adaptation of a virus to a new host is a very rare event, suggesting that there are high barriers that prevent viruses from gaining the ability to infect and spread naturally in hosts to which they are not adapted. In this study, the novel point mutation virus is most likely not a panda-adapted virus spreading among pandas, but more likely a spill-over from dogs. Because host adaptation involved complex interactions among both surface-exposed and buried capsid mutations that together altered cell infection and immune escape properties of the viruses [33]. In this study, the virus VP2 gene coding change at nt 3894 (VP2 residue 370, Gln→Arg) was interesting because it has not been detected previously in any other strains. We speculated that the mutation has two aspect functions. On the one hand, residue 370 was close to residues 375 and 377, it might mediate an effect on receptor binding through the neighboring residues, and is likely to have had an effect on the parvovirus host range [35]. So, we made the inferences that R370 might be involved in a required conformational change, or it might mediate an effect on receptor binding through the neighboring residues, and is likely to have had an effect on the parvovirus host range. This observation suggests that the glutamine to arginine mutation may also affect host DNA-protein interaction. As is the case for wild animal, this mutation is not selected for the population, but may have arisen independently from various backgrounds.

As the phylogenetic tree shows, most of the viruses isolated in China formed a large cluster, while some strains clustered together with viruses from regions outside China. Most of the CPVs isolated in China formed a specific cluster and certain mutations detected in Chinese CPVs probably arose during the process of local adaptation, as indicated by previous surveys [36]. Considering that the CPV-2 vaccine appears to provide a comparatively lower and shorter immunity against heterologous CPVs, there is evidences to suggest that complete immunity may not be provided to dogs even if CPV-2 vaccines are used [37-39]. In many countries, such as Europe, CPV-2a has been overtaken by CPV-2b or CPV-2c, some researches have been to evaluate antigenic relationships among the original canine parvovirus type 2 (CPV-2) and the variants CPV-2a, -2b, and -2c, cross-antigenic evaluation revealed clear differences among the CPV variants [40]. Nevertheless, our study showed that the giant panda and dogs are all new CPV-2a type, while the vaccines available for giant pandas and dogs are CPV-2 type vaccine in China (Nobivac®, Hol-land) [41]. The effectiveness of CPV-2 vaccine against CPV-2a type has not been evaluated in China.

In sum, wildlife in captive facilities in China is generally not reliably or safely vaccinated. Strain difference between field virus and vaccine candidate virus could be one of the important attributable reasons for some immunization failure. Infectious diseases pose a significant risk to these animals, of which many are endangered species, the mechanisms of the virus into the giant panda population and the adaptation (mutation) of the virus to that species are important topics for future research.

Materials and methods

Ethics statement

The animal from which specimens were collected, was handled in accordance with animal protection law of the People’s Republic of China (a draft of an animal protection law in China released on September 18, 2009). This study was approved by the National Institute of Animal Health Animal Care and Use Committee at Sichuan Agricultural University (approval number 2010–020).

Clinical samples

A total of 36 faecal samples of giant pandas and 97 rectal swabs were collected from dogs suspected to be
infected with CPV were gathered simultaneously. Detailed information on the origin and the accession numbers of the CPV-positive samples is shown in Table 2. All activities followed the legal requirements and institutional guidelines set out by the government of P.R. China. The samples were collected in China during a period of 7 months from November 2011 to May 2012. The collected samples were emulsified in 2 ml of 0.1 M PBS of pH 7.4 and centrifuged at 6000 g for 15 min at 4°C. The supernatant was collected and used for PCR amplification.

**Template DNA preparation**

Hundred microlitres of the processed supernatant was used for template DNA preparation by boiling at 96°C for 10 min and chilling immediately in crushed ice [42,43]. The supernatants were diluted 1:10 in distilled water to reduce residual inhibitors of DNA polymerase activity [12].

**Primer pair and PCR amplification**

PCR amplification was performed using KOD-Plus-Ver.2 (TOYOBO, Japan) and primer pair Hfor (5′-CAGGTG ATGAATTTGCTACA-3′)/Hrev (5′-CATTGGGATA -AACTGGTGGT-3′) that amplifies 611 bp fragment of the gene encoding capsid protein [11]. PCR amplification was consisted of 30 cycles of denaturation (95°C 45 s), annealing(51°C 45 s), extension (72°C 45 s) and final extension (72°C 10 min) and the products were analyzed by electrophoresis using 1.5% agarose gel in Tris acetate EDTA (TAE) buffer (1×).

**Sequencing and phylogenetic analysis**

PCR products of the correct size (611 bp in length) were amplified and cloned using TArget Clone-Plus-(TOYOBO, Japan),then custom sequenced with primer pair Hfor/ Hrev. The sequences were aligned with sequences of prototype CPV strains (M38246-FPV; M38245 (CPV-2), M24003 (CPV-2a), M74849 (CPV-2b), AY742953 (New CPV-2a), AY742955 (New CPV-2b) and FJ222821 (CPV-2c) obtained from the Genbank.

Sequence of one of the representative canine parvovirus field isolate GU139553 (New CPV-2a) is shown aligned with the reference strains M38246 (FPV), M38245 (CPV-2), M24003 (CPV-2a), M74849 (CPV-2b), AY742953 (New CPV-2a), AY742955 (New CPV-2b) and FJ222821 (CPV-2c) obtained from the Genbank.

**Table 2 Alignment of the deduced amino acid sequences of partial VP2 gene**

| Aa residue | 267 | 297 | 300 | 305 | 324 | 370 | 375 | 426 | 442 |
|------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Nt position| 3585-3588 | 3675-3577 | 3684-3856 | 3699-3701 | 3756-3769 | 3894-3897 | 3909-3912 | 4064-4067 | 4112-4115 |
| M38245(CPV-2) | F | S | A | D | Y | Q | N | N | T |
| M24003(CPV-2a) | F | S | G | Y | Y | Q | D | N | T |
| M74849(CPV-2b) | F | S | G | Y | Y | Q | D | D | T |
| FJ222821(CPV-2c) | F | A | G | Y | Y | Q | D | E | T |
| AY8054218(FPV) | F | A | G | Y | Y | Q | D | N | T |
| AY742953(New-CPV-2a) | F | A | G | Y | Y | Q | D | N | T |
| AY742955(New-CPV-2b) | F | A | G | Y | Y | Q | D | D | T |
| JX624761(A10) | Y | A | G | Y | I | Q | D | N | A |
| JX624762(A11) | Y | A | G | Y | I | Q | D | N | A |
| JX624763(A12) | Y | A | G | Y | I | Q | D | N | A |
| JX624764(B01) | Y | A | G | Y | I | Q | D | N | A |
| JX624765 (B02) | Y | A | G | Y | I | Q | D | N | A |
| JX624766(B03) | F | A | G | Y | I | Q | D | N | T |
| JX624767(B04) | Y | A | G | Y | I | Q | D | N | T |
| JX624768(B05) | Y | A | G | Y | I | Q | D | N | A |
| JX624769(B06) | F | A | G | Y | I | Q | D | N | T |
| JX624770(B07) | Y | A | G | Y | I | Q | D | N | A |
| JX624771(B11) | F | A | G | Y | I | R | D | N | A |
| JX624772(B12) | Y | A | G | Y | I | Q | D | N | A |

Guo et al. Virology Journal 2013, 10:163
http://www.virologyj.com/content/10/1/163
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conceived and designed the experiments: LG SLY. Performed the experiments: LG SLY ZH XZ LF ZQF. Analyzed the data: LG SLY MLZ ZHX. Contributed reagents/materials/analysis tools: SJC ZH ZJ YPR CDW XTW. Wrote the paper: LG SLY. All of the authors read and approved the final version of the manuscript.

Acknowledgments
This work was supported by Program for Changjiang Scholars and Innovative Research Team in University, China (IRT0848). Specific projects of public welfare of the Ministry of Science and Technology of the P.R. China (20090188), Program of Science and Technology Department of Sichuan Province (2010ZS0055), National Key Technology & R&D Program (2012AC010601), Chengdu Giant panda Breeding Research Foundation and National Basic Research Program of China (973 program, 2012CB722207)

Author details
1 College of Veterinary Medicine, Sichuan Agricultural University, Ya’an, China.
2 Center of Veterinary Medicine, Sichuan Agricultural University, Ya’an, China.
3 Province (2010SZ0050), National Key Technology R&D Program in University, China.
4 Southwestern University for Nationalities, Chengdu, Sichuan, China.
5 Key laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan Agricultural University, Ya’an, China.

Received: 28 February 2013 Accepted: 22 May 2013
Published: 26 May 2013

References
1. Decaro N, Buonavoglia C: Canine parvovirus—a review of epidemiological and diagnostic aspects, with emphasis on type 2c. Vet Microbiol 2012, 155:1–12.
2. Kang BK, Song DS, Lee CS, Jung KI, Park SJ, Kim EM, Park BK: Prevalence and genetic characterization of canine parvoviruses in Korea. Virus Genes 2008, 36:127–133.
3. Decaro N, Elia G, Campoio M, Desario C, Martella V, Buonavoglia C: New approaches for the molecular characterization of canine parvovirus type 2 strains. J Vet Med B 2005, 52:316–319.
4. Parrish CR, Aquadro CF, Strassheim M, Evermann J, Sgro J, Mohammed H: Rapid antigenic-type replacement and DNA sequence evolution of canine parovirus. J Virol 1991, 65:6544–6552.
5. Parish CR, O’Connell PH, Evermann JF, Carmichael LE: Natural variation of canine parovirus. Science 1985, 230:1046–1048.
6. Parker JS, Murphy WJ, Wang D, O’Brien SJ, Parrish CR: Canine and feline paroviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 2001, 75:3896–3902.
7. Truyen U: Evolution of canine parovirus: loss and gain of the feline host. Tienzer Plazh 1996, 24:316.
8. Martella V, Cavalli A, Decaro N, Elia G, Desario C, Campoio M, Bozzo G, Tantrao E, Buonavoglia C: Immunogenicity of an intranasally administered modified live canine parovirus type 2 vaccine in pups with maternally derived antibodies. Clin Diag Lab Immun 2005, 12:1243–1245.
9. Ohshima T, Hikasa M, Kawaanami K, Kishi M, Toda Y, Mochizuki D: Chronological analysis of canine parovirus type 2 isolates in Japan. J Vet Med Sci Japan Soc Vet Sci 2008, 70:69.
10. Truyen U: Evolution of canine parovirus—a need for new vaccines? Vet Microbiol 2006, 117:9–13.
11. Buonavoglia C, Martella V, Prattelli A, Tempesto M, Cavalli A, Buonavoglia D, Bozzo G, Elia G, Decaro N, Carmichael L: Evidence for evolution of canine parovirus type 2 in Italy. J Gen Virol 2001, 82:2021.
12. Decaro N, Martella V, Decaro C, Calliabaco A, Camaro M, Mannja L, Aлоja D, Buonavoglia C: First detection of canine parovirus type 2c in pups with haemorrhagic enteritis in Spain. J Vet Med B 2006, 53:468–472.
13. Nakamura M, Tohya Y, Miyazawa T, Mochizuki M, Phung H, Nguyen N, Hung H, Nguyen N, Nguyen P, Nguyen P: A novel antigenic variant of canine parovirus from a Vietnamese dog. Arch Virol 2004, 149:2261–2269.
14. Touhi L, Bouzid J, Daudo R, Desario C, Bloulli AF, Decaro N, Ghorbel A, Buonavoglia C, Bahoul L: Molecular characterization of canine parovirus-2 variants circulating in Tunisia. Virus Genes 2009, 38:249–258.
15. Decaro N, Desario C, Addie D, Martella V, Vieira M, Elia G, Zicola A, Davis C, Thompson G, They E: Molecular epidemiology of canine parovirus, Europe. Emerg Infect Dis 2007, 13:1222–1224.
16. Decaro N, Desario C, Amorisco F, Losardo M, Elia G, Parisi A, Ventrella G, Martella V, Buonavoglia C: Detection of a canine parovirus type 2c with a non-coding mutation and its implications for molecular characterization. Vet J 2013 (In Press).
17. Hong C, Decaro N, Desario C, Tanner P, Pardo MC, Sanchez S, Buonavoglia C, Saliki JT: Occurrence of canine parovirus type 2c in the United States. J Virol Diagn Invest 2007, 19:535–539.
18. Wu J, Gao GW, Jiang YK, Luo JM, Yang SQ, Wu GQ, Huang XW, He GX, Li YS, Ye ZY, et al: Serosurvey of infection of parovirus in giant pandas. Chin Prev Vet Med 1988, 2:89–39.
19. Mainka SA, Qiu X, He T, Appel MJ: Serologic survey of giant pandas (Ailuropoda melanoleuca), and domestic dogs and cats in the Wolong Reserve, China. J Wildlife Dis 1994, 30:86–89.
20. Loffeker IK, Howard J, Montal J, Hayek LA, Dubovi E, Zhang Z, Yan Q, Guo W, Willet DE: Serosurvey of ex situ giant pandas (Ailuropoda melanoleuca) and red pandas (Ailurus fulgens) in China with implications for species conservation. J Zoo Wildl Med 2007, 38:559–566.
21. Qin Q, Li D, Zhang H, Hou R, Zhang Z, Zhang C, Zhang J, Wei F: Serosurvey of selected viruses in captive giant pandas (Ailuropoda melanoleuca) in China. Vet Microbiol 2010, 142:199–204.
22. Chinchkar S, Mohana Subramanian B, Hanumantha Rao N, Ranganjan P, Triagaranjan D, Srinivasan V: Analysis of VP2 gene sequences of canine parovirus isolates in India. Arch Virol 2006, 151:1881–1887.
23. Clegg S, Coyne K, Parker J, Dawson S, Goddiss S, Pinchbeck G, Cripps P, Gaskell R, Redford A: Molecular Epidemiology and Phylogeny Reveal Complex Spatial Dynamics in Areas Where Canine Parovirus Is Endemic. J Virol 2011, 85:7892–7899.
24. Martella V, Decaro N, Elia G, Buonavoglia C: Surveillance activity for canine parovirus in Italy. J Vet Med B 2005, 52:312–315.
25. Mochizuki M, Oshihama T, Une Y, Yachi A: Recombination between vaccine and field strains of Canine parovirus is revealed by isolation of virus in canine and feline cell cultures. J Vet Med Sci 2008, 70:305–314.
26. Decaro N, Desario C, Bili M, Mari V, Elia G, Cavalli A, Martella V, Buonavoglia C: Western European epidemiological survey for parovirus and coronavirus infections in dogs. J Vet J 2011, 187:195–199.
27. Zhang R, Yang S, Zhang W, Zhang T, Xie Z, Feng H, Wang S, Xia X: Phylogenetic analysis of the VP2 gene of canine parovirus circulating in China. Virus Genes 2010, 40:397–402.
28. Ikeda Y, Mochizuki M, Naito R, Nakamura K, Miyazawa T, Mikami T, Takahashi E: Predominance of canine parovirus (CPV) in unvaccinated cat populations and emergence of new antigenic types of CPVs in cats. Virology 2001, 278:13–19.
29. Bartlani M, Scaglioni A, Trastato E, Turilli C, Jacobbini I, Casadio R, Prospero S: Analysis of canine parovirus sequences from wolves and dogs isolated in Italy. J Gen Virol 2001, 82:1555–1560.
30. Jeong SY, Ahn SJ, Kim D: Genetic analysis of VP2 gene of canine parovirus isolates in Korea. J Vet Med Sci Japanese Soc Vet Sci 2008, 70:719.
31. Decaro N, Desario C, Parisi A, Martella V, Lorusso A, Miccolupo A, Mari V, Loredana Coianni M, Cavalli A, Di Trani L: Genetic analysis of canine parovirus type 2c. Virology 2009, 385:5–10.
32. Hoeber K, Shackleton LA, Parrish CR, Holmes EC: Phylogenetic analysis reveals the emergence, evolution and dispersal of carnivore paroviruses. J Gen Virol 2008, 89:2280–2289.
33. Stucker KM, Pagán I, Clifford JG, Kaelber JT, Liddle TD, Hafenstein S, Holmes EC, Parrish CR: The role of evolutionary intermediates in the host adaptation of canine parovirus. J Virol 2012, 86:1514–1521.
34. Tiao J, Chapman MS, Agbandje M, Keller W, Smith K, Wuu J, Luo M, Smith TJ, Rossmann MG, Compans RW, et al: The three-dimensional structure of canine parovirus and its functional implications. Science 1991, 251:1456–1464.
35. Kaelber JT, Demogines A, Harbison CE, Allison AB, Goodman LB, Ortega AN, Sawyer SL, Parrish CR: Evolutionary reconstructions of the transferrin receptor of Caniforms supports canine parovirus being a re-emerged and not a novel pathogen in dogs. PLoS Pathog 2012, 8:e1002666.
38. Decaro N, Citrone F, Desario C, Elia G, Lorusso E, Colaianni M, Martella V, Buonavoglia C: Severe parvovirus in a 12-year-old dog that had been repeatedly vaccinated. *Vet Rec* 2009, 164:593–595.

39. Decaro N, Desario C, Elia G, Martella V, Mari V, Lavazza A, Nardi M, Buonavoglia C: Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c. *Microbiol-Quart J Microbiol Sci* 2008, 31:125–130.

40. Cavalli A, Martella V, Desario C, Camero M, Bellaccinco AL, De Palo P, Decaro N, Elia G, Buonavoglia C: Evaluation of the antigenic relationships among canine parvovirus type 2 variants. *Clin Vaccine Immunol* 2008, 15:534–539.

41. Wang CD, Zhang ZH: Current status of canine distemper vaccine immune among giant pandas and red pandas. *Sichuan J Zool* 2006, 25:668–672.

42. Decaro N, Desario C, Campolo M, Elia G, Martella V, Ricci D, Lorusso E, Buonavoglia C: Clinical and virological findings in pups naturally infected by canine parvovirus type 2 Glu-426 mutant. *J Vet Diagen Invest* 2005, 17:133.

43. Schunck B, Kraft W, Truyen U: A simple touch-down polymerase chain reaction for the detection of canine parvovirus and feline panleukopenia virus in feces. *J Virol Met* 1995, 55:427–433.

44. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGAS: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* 2011, 28:2731–2739.

Cite this article as: Guo *et al.*: Identification of canine parvovirus with the Q370R point mutation in the VP2 gene from a giant panda (*Ailuropoda melanoleuca*). *Virology Journal* 2013 10:163.